4D Molecular Therapeutics, Inc. - COMMON STOCK (FDMT)

CUSIP: 35104E100

Q3 2024 13F Holders as of 30 Sep 2024

Holder snapshot 7 signals
Share change
+669,597
Put/Call ratio
81%
SEC-reported price per share
$10.81
Number of holders
135
Value change
-$34,446,524
Number of buys
74
Open additional details 1 more signal available
Number of sells
67
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
54,876,111

Security key

35104E100

Report period

Q3 2024

Institutions

135

Top holders

10

Ownership snapshot

Top reported holders of FDMT - 4D Molecular Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
VIKING GLOBAL INVESTORS LP
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
0/15
Latest evidence
30 Jun 2024
3/4/5 13F Highest disclosed value: $107,011,449 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. has the largest disclosed position value at $107.01M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Disclosed position value Top 5
VIKING GLOBAL INVESTORS LP $78.2M
RA CAPITAL MANAGEMENT, L.P. $107.01M
BlackRock Finance, Inc. $102.79M
Venrock Adviser, LLC $92.36M
GOLDMAN SACHS GROUP INC $86.78M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
VIKING GLOBAL INVESTORS LP
3/4/5 13F
10%+ Owner · Company
—
denominator unverified
$78,195,176
4,247,914 shares
— 04 Jan 2024
RA CAPITAL MANAGEMENT, L.P.
13F
Company
13F
—
denominator unverified
$107,011,449
5,098,211 shares
— 30 Jun 2024
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$102,785,867
4,896,897 shares
— 30 Jun 2024
Venrock Adviser, LLC
13F
Company
13F
—
denominator unverified
$92,356,000
4,400,000 shares
— 30 Jun 2024
GOLDMAN SACHS GROUP INC
13F
Company
13F
—
denominator unverified
$86,777,991
4,134,254 shares
— 30 Jun 2024
Deep Track Capital, LP
13F
Company
13F
—
denominator unverified
$85,248,807
4,061,401 shares
— 30 Jun 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
135
Shares
57,948,767
Rows available
135
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders
138
Q3 2024 holders
135
Holder diff
-3
Investor Q2 2024 Shares Q3 2024 Shares Share Diff Share Chg % Q2 2024 value Q3 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .